Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Department of Surgery, Centre Médico-Chirurgical de Tronquières, Aurillac, France.
Surgery. 2021 May;169(5):1044-1051. doi: 10.1016/j.surg.2020.12.012. Epub 2021 Feb 27.
Portal vein embolization before liver resection is considered the therapy of choice for patients with inadequate future liver remnants. The concept of radioembolization with Yttrium-90 to achieve the same goal has limited data.
We retrospectively compared patients who underwent portal vein embolization and Yttrium-90 lobectomy before resection of hepatocellular carcinoma in patients with chronic liver disease.
Seventy-three patients underwent portal vein embolization and 22 patients underwent Yttrium-90. Forty-seven percent of patients before portal vein embolization required additional procedures for tumor control, and 27% of patients after Yttrium-90 required additional procedure to mainly induce further hypertrophy. Both therapies achieved the goal of future liver remnants >40%, but the degree of hypertrophy was significantly higher in Yttrium-90 patients (63% for Yttrium-90, 36% for portal vein embolization, P < .01). Tumor response was significantly better with Yttrium-90, achieving complete response in 50% of patients. Resectability rate was higher after portal vein embolization (85% for portal vein embolization, 64% for Yttrium-90, P = .03). Tumor progression was the most common reason precluding surgery. Complete tumor control was the reason not to pursue surgery in 18% of patients after Yttrium-90.
Both preoperative portal vein embolization and Yttrium-90, increases liver resectability rates by inducing hypertrophy of future liver remnants in patients with hepatocellular carcinoma and chronic liver disease. Yttrium-90 lobectomy achieved better tumor control and provided more time to assess therapy response, optimizing the indication for surgery.
在进行肝脏切除术前进行门静脉栓塞术被认为是未来肝残存量不足患者的首选治疗方法。钇-90 放射性栓塞术实现相同目标的概念数据有限。
我们回顾性比较了慢性肝病患者行肝癌切除术前行门静脉栓塞术和钇-90 叶切除术的患者。
73 例患者行门静脉栓塞术,22 例患者行钇-90 叶切除术。门静脉栓塞术前 47%的患者需要进行额外的肿瘤控制手术,而 27%的患者在接受钇-90 治疗后需要进行额外的手术以主要诱导进一步的肝肿大。两种治疗方法都达到了未来肝残存量>40%的目标,但钇-90 患者的肝肿大程度明显更高(钇-90 为 63%,门静脉栓塞术为 36%,P<.01)。钇-90 的肿瘤反应明显更好,50%的患者达到完全缓解。门静脉栓塞术后的可切除率更高(门静脉栓塞术为 85%,钇-90 为 64%,P=.03)。肿瘤进展是最常见的手术禁忌原因。18%的患者在接受钇-90 治疗后,完全肿瘤控制是不进行手术的原因。
术前门静脉栓塞术和钇-90 均可通过诱导肝癌和慢性肝病患者未来肝残存量的肝肿大来提高肝切除率。钇-90 叶切除术实现了更好的肿瘤控制,并提供了更多的时间来评估治疗反应,从而优化了手术适应证。